INTRODUCTION 1
Myocardial disease occurring in patients with Systemic Sclerosis (SSc) is classically Patients and study design 23 Patients fulfilling the ACR/EULAR criteria for SSc, [15] consecutively admitted to 20 24 DeSScipher-EUSTAR centres from December 1 st , 2012 to November 30 th , 2015, were 25 enrolled, according to local ethical requirements. 26 Patients with the following characteristics were excluded: significant pulmonary 27 parenchymal (forced vital capacity and/or diffusing lung capacity for CO < 70%) or 28 vascular involvement (estimated systolic pulmonary arterial pressure > 40 mmHg), 29 intestinal involvement (malabsorption syndrome or paralytic ileus or renal involvement 30 (serum creatinine level >1.2 mg/dl and/or dialysis or previous scleroderma renal crisis) or any sign/symptom/ electrocardiographic (ECG) finding of myocardial disease, basal 1 pulmonary rales and/or leg edema indicative of congestive heart failure.
Patients enrolled in the study were investigated according to the DeSScipher protocol, 3 shared by all participating centres. In particular, they were assessed for the items listed in 4 the European Scleroderma Trials and Research group (EUSTAR) protocol, [16] including 5 European Scleroderma Study Group (EScSG) activity criteria. [17] Moreover, as far as 6 myocardial disease is concerned, each patient was examined at baseline by means of 7 medical history, clinical examination, ECG, Holter ECG and B-mode echocardiography at 8 baseline, and was reassessed every 3 months with respect to medical history, clinical 9 examination, and ECG, and every 6 months by Holter ECG and B-mode echocardiography 10 until the end of each follow-up-year. According to local policies, patients had to undergo 11 either standard vasodilator therapy i.e. CCB such as nifedipine up to 60 mg/qd or 12 comparable doses of other drugs of the same class and/or ACEinh such as captopril up to 13 100 mg/qd, or no vasodilator therapy. Two hundred and 50 patients per arm had to be 14 enrolled. Despite the strictly defined entry criteria, 2 major protocol deviations occurred. As 15 far as treatment is concerned, some patients with baseline myocardial disease were 16 enrolled. As far as treatment is concerned, 63 patients undergoing AgIIrb±CCB treatment 17 were enrolled.Because of the influence on the same pathophysiologic pathway, they were 18 considered in the same class of ACEinh and included in the arm of those treated with CCB 19 and/or ACEinh, with the whole group being referred to as standard vasodilator therapy.
20
Moreover, some patients treated with targeted vasodilator drugs (i.e. prostanoids or 21 endothelin receptor antagonists or phosphodiesterase type 5 inhibitors), were enrolled.
22
Out of them, those undergoing standard vasodilator therapy were included in the same 23 arm which was referred to as vasodilator therapy; those treated with targeted vasodilator 24 drugs only were excluded because of the intermittent drug regimen in most of them. The Finally, the incidence of withdrawal from treatment was used as safety endpoint. From December 1 st , 2012 to November 30 th , 2015, a total of 654 SSc patients, with a 18 mean age of 56±13 years a disease duration from the first non-RP manifestation ranging 19 from 0.5 to 61 years (mean 10±9 SD), were enrolled in the study and followed-up for at 20 least six months.
21
One hundred and 53 patients did not undergo any vasodilator; 448 were prescribed 22 vasodilators including 89 treated with either prostanoids and/or endothelin receptor 23 antagonists and/or phosphodiesterase inhibitors. The 43 patients treated only with 24 targeted vasodilators were excluded.
25 Table 1 shows the demographic, clinical, serological and therapeutic features as assessed 26 at enrollment and during follow-up as far as the drug regimen is concerned, in the 27 remaining 601 patients subdivided according to the therapeutic subgroup. Given the 28 presence of missed items, the prevalence of each feature has been calculated among 29 patients in whom it had been underlined. Hypercholesterolemia was noticed in few 30 patients; no data were available for statin use.
With respect to patients undergoing no vasodilators, those treated with vasodilator therapy 1 resulted to be more frequently aged ≥50 years (p=0.005), affected by systemic arterial 2 hypertension (p<0.001) and to be undergoing in a greater percentage corticosteroids 3 ±immunosuppressors (p<0.001) and low dose ASA (p<0.001) i.e. they presented a 4 greater prevalence of disease features potentially associated with a worse cardiovascular 5 outcome. any bias deriving from potential differences in the treatment policies among the distinct 28 centres involved in the study, vasodilators were found to be associated with a lower incidence of ventricular arrhythmias, low dose ASA with a nearly significant, lower 1 incidence of cardiac blocks and/or Q waves and/or pacemaker implantation; active 2 disease, as defined by a EScSG activity index ≥3 at enrollment with a higher incidence of 3 a reduced LVEF and/or CHF. 4 We underwent our prospective study because of the commonly shared opinion on the we pointed out an association between vasodilators and a lower incidence of ventricular 14 arrhythmias, which likely depend on ischemic processes. [13, 14] In conclusion, our prospective, observational study suggests a protective role of 23 vasodilators and low dose ASA on distinct manifestations of SSc myocardial disease and 24 prospects the opportunity to conduct well designed RCTs on both therapeutic strategies. 
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